Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2023/08/056401
CTRI/2023/08/056401Not yet recruitingUnknown

Patient reported outcomes of acute esophageal toxicities in patients of Non small cell lung cancer treated with radical radiotherapy with or without concurrent or sequential chemotherapy - NI

ot applicable0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Unknown
Status
Not yet recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • •Patient of locally advanced non small cell lung cancer who will be treated with concurrent chemoradiation (EBRT 60Gy/30frs/6weeks along with Platinum doublet based chemotherapy) or sequential chemoradiation(3-4 cycles of Platinum doublet based chemotherapy followed by EBRT 55Gy/20Frs/4weeks) or radical radiotherapy alone (EBRT 55Gy/20Frs/4weeks)
  • •All patients who will be receiving Intensity modulated radiotherapy (IMRT) with daily image guidance

Exclusion Criteria

  • •Post operative radiotherapy
  • •Palliative radiotherapy
  • •Stereotactic body radiotherapy (SBRT) for early NSCLC
  • •Reirradiation
  • •Radiotherapy for small cell lung cancer
  • •Patients who will receive 3D conformal radiotherapy (3DCRT) for NSCLC
  • •Consolidative radiotherapy for oligometastatic disease

Investigators

Similar Trials

Recruiting
Phase 1
Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients treated with definitive chemo-radiotherapyoropharyngal cancer
CTIS2023-506258-19-00Institut Jules Bordet121
Completed
Not Applicable
Evaluation and prospects for the introduction of VMAT for the purpose of reducing pericardial effusion after radical CRT for esophageal cancer
JPRN-UMIN000043452Keiyukai Sapporo Hospital158
Active, not recruiting
Not Applicable
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks - Magnum IIGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263
EUCTR2004-000492-33-LTALTANA Pharma AG800
Active, not recruiting
Not Applicable
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks
EUCTR2004-000492-33-LVALTANA Pharma AG800
Active, not recruiting
Not Applicable
Healing of patients suffering from gastroesophageal reflux esophagitisgrade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeksGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263
EUCTR2004-000493-32-ATALTANA Pharma AG1,980